Publications by authors named "Immaculada Calvo Penades"
Article Synopsis
- Juvenile idiopathic arthritis (JIA) is a common chronic condition in children that can lead to serious long-term issues if not properly treated, highlighting the need for early intervention.
- A study in Spain assessed the costs associated with moderate-to-severe JIA in children, including both direct costs (like medication and doctor visits) and indirect costs (like travel and lost work hours for caregivers).
- Results showed that the average annual cost for treating JIA was €7516.40, with medication being the largest expense, mostly consisting of biologic treatments like adalimumab and etanercept.
Background: Some children with juvenile idiopathic arthritis either do not respond, or are intolerant to, treatment with disease-modifying antirheumatic drugs, including anti-tumour necrosis factor (TNF) drugs. We aimed to assess the safety and efficacy of abatacept, a selective T-cell costimulation modulator, in children with juvenile idiopathic arthritis who had failed previous treatments.
Methods: We did a double-blind, randomised controlled withdrawal trial between February, 2004, and June, 2006.